Tilray, Inc engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc is headquartered in Nanaimo, Canada.
Industry, Sector and Symbol
Industry Medicinals & botanicals
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone844-845-7291
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$43.13 million
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date11/12/2019 (Estimated)
OptionableOptionable
Tilray (NASDAQ:TLRY) Frequently Asked Questions
What is Tilray's stock symbol?
Tilray trades on the NASDAQ under the ticker symbol "TLRY."
How were Tilray's earnings last quarter?
Tilray Inc (NASDAQ:TLRY) released its quarterly earnings results on Tuesday, August, 13th. The company reported ($0.32) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.23) by $0.09. The business earned $45.90 million during the quarter, compared to analyst estimates of $40.25 million. Tilray had a negative return on equity of 37.64% and a negative net margin of 121.73%. The company's revenue was up 373.2% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.17) EPS. View Tilray's Earnings History.
When is Tilray's next earnings date?
What price target have analysts set for TLRY?
16 brokerages have issued 1-year price objectives for Tilray's shares. Their forecasts range from $37.00 to $81.10. On average, they anticipate Tilray's stock price to reach $57.9680 in the next twelve months. This suggests a possible upside of 90.1% from the stock's current price. View Analyst Price Targets for Tilray.
What is the consensus analysts' recommendation for Tilray?
16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Tilray in the last year. There are currently 3 sell ratings, 9 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Tilray.
What are Wall Street analysts saying about Tilray stock?
Here are some recent quotes from research analysts about Tilray stock:
- 1. According to Zacks Investment Research, "Tilray, Inc. is a pharmaceutical company. It develops cannabis based medicines, drugs, drops and oil products. Tilray, Inc. is based in NANAIMO, Canada. " (8/16/2019)
- 2. Jefferies Financial Group Inc analysts commented, "We initiate at Underperform, PT $61. With arguably inferior positioning in parts of its business vs. certain peers (questionable Canada rec approach, less impressive US optionality, too much value credited to ABI/ABG), we struggle to justify the current valuation. We appreciate it is well placed in medical but future value here will be driven by IP for which little visibility near term. Its share structure also raises risk of increased volatility." (3/8/2019)
Has Tilray been receiving favorable news coverage?
News stories about TLRY stock have been trending negative on Tuesday, according to InfoTrie Sentiment Analysis. InfoTrie identifies positive and negative news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Tilray earned a daily sentiment score of -2.9 on InfoTrie's scale. They also gave news articles about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the company's share price in the near term. View News Stories for Tilray.
Are investors shorting Tilray?
Tilray saw a decrease in short interest in the month of August. As of August 31st, there was short interest totalling 6,249,500 shares, a decrease of 6.9% from the July 31st total of 6,712,900 shares. Based on an average trading volume of 1,700,000 shares, the short-interest ratio is currently 3.7 days. Approximately 28.6% of the shares of the stock are sold short. View Tilray's Current Options Chain.
Who are some of Tilray's key competitors?
Some companies that are related to Tilray include Canopy Growth (CGC), Aurora Cannabis (ACB), STADA Arzneimittel (STDAF), Cronos Group (CRON), USANA Health Sciences (USNA), Sundial Growers (SNDL), Canopy Rivers (RIV), Chromadex (CDXC), Foamix Pharmaceuticals (FOMX), True Drinks (TRUU), Mediwound (MDWD), Natural Alternatives International (NAII), Mannatech (MTEX), Cyanotech (CYAN) and FitLife Brands (FTLF).
What other stocks do shareholders of Tilray own?
Who are Tilray's key executives?
Tilray's management team includes the folowing people:
- Mr. Edward Wood Pastorius Jr., Chief Revenue Officer (Age 50)
- Mr. Brendan Kennedy, Pres, CEO & Director (Age 46)
- Mr. Mark Castaneda, CFO, Sec. & Treasurer (Age 53)
- Dr. Catherine Jacobson, Director of Clinical Research & Member of Medical Advisory Board
When did Tilray IPO?
(TLRY) raised $135 million in an initial public offering on Thursday, July 19th 2018. The company issued 9,000,000 shares at a price of $14.00-$16.00 per share. Cowen and Company served as the underwriter for the IPO and Roth Capital Partners and Northland Securities were co-managers.
Who are Tilray's major shareholders?
Tilray's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include ETF Managers Group LLC (2.03%), Morgan Stanley (0.34%), Think Investments LP (0.16%), Vanguard Group Inc. (0.08%), Stelac Advisory Services LLC (0.07%) and BNP Paribas Arbitrage SA (0.05%). Company insiders that own Tilray stock include Brendan Kennedy, Christine StClare, Edward Wood Pastorius Jr and Mark Castaneda. View Institutional Ownership Trends for Tilray.
Which institutional investors are selling Tilray stock?
TLRY stock was sold by a variety of institutional investors in the last quarter, including Hellman Jordan Management Co. Inc. MA and Ladenburg Thalmann Financial Services Inc.. Company insiders that have sold Tilray company stock in the last year include Brendan Kennedy, Christine StClare, Edward Wood Pastorius Jr and Mark Castaneda. View Insider Buying and Selling for Tilray.
Which institutional investors are buying Tilray stock?
TLRY stock was purchased by a variety of institutional investors in the last quarter, including ETF Managers Group LLC, Think Investments LP, Morgan Stanley, Vanguard Group Inc., Stelac Advisory Services LLC, BNP Paribas Arbitrage SA, Swiss National Bank and Southpoint Capital Advisors LP. Company insiders that have bought Tilray stock in the last two years include Brendan Kennedy and Edward Wood Pastorius Jr. View Insider Buying and Selling for Tilray.
How do I buy shares of Tilray?
Shares of TLRY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Tilray's stock price today?
One share of TLRY stock can currently be purchased for approximately $30.50.
How big of a company is Tilray?
Tilray has a market capitalization of $2.98 billion and generates $43.13 million in revenue each year. The company earns $-67,720,000.00 in net income (profit) each year or ($0.82) on an earnings per share basis. View Additional Information About Tilray.
What is Tilray's official website?
How can I contact Tilray?
Tilray's mailing address is 1100 Maughan Road, Nanaimo A1, V9X IJ2. The company can be reached via phone at 844-845-7291.
MarketBeat Community Rating for Tilray (NASDAQ TLRY)
MarketBeat's community ratings are surveys of what our community members think about Tilray and other stocks. Vote "Outperform" if you believe TLRY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TLRY will underperform the S&P 500 over the long term. You may vote once every thirty days.
